

Multimorbidity: clinical assessment and management



Consultation on draft guideline deadline for comments 17.00 on 12/05/2016 email: Multimorbidities@nice.org.uk

		<p>Please read the checklist for submitting comments at the end of this form. We cannot accept forms that are not filled in correctly.</p> <p>We would like to hear your views on these questions:</p> <ol style="list-style-type: none"> 1. Do any recommendations represent a substantial increase in costs, and do you consider that the reasons given in the guideline are sufficient to justify this? 2. Which areas will have the biggest impact on practice and be challenging to implement? Please say for whom and why. 3. What would help users overcome any challenges? (For example, existing practical resources or national initiatives, or examples of good practice.) <p>See section 3.9 of Developing NICE guidance: how to get involved for suggestions of general points to think about when commenting.</p>
<p>Stakeholder organisation(s) (or your name if you are commenting as an individual):</p>		<p><u>Age UK</u></p>
<p>Name of commentator (leave blank if you are commenting as an individual):</p>		<p>Tom Gentry</p>
<p>Comment number</p>	<p>Document (full version, short)</p>	

Please return to: **[insert email address]**

Multimorbidity: clinical assessment and management



Consultation on draft guideline deadline for comments 17.00 on 12/05/2016 email: Multimorbidities@nice.org.uk

the evidence (Polypharmacy and medicines optimisation: Making it safe and sound, King's Fund, 2013) considers

Please return to: **[insert email address]**

Multimorbidity: clinical assessment and management

Consultation on draft guideline deadline for comments 17.00 on 12/05/2016 email:

Multimorbidity: clinical assessment and management



Consultation on draft guideline deadline for comments 17.00 on 12/05/2016 email: Multimorbidities@nice.org.uk

Checklist for submitting comments

- Use this comment form and submit it as a Word document (not a PDF).
- Include page and line number (not section number) of the text each comment is about.
- Combine all comments from your organisation into 1 response. We cannot accept more than 1 response from each organisation.
- Do not paste other tables into this table – type directly into the table.
- Underline and highlight any confidential information or other material that you do not wish to be made public.
- Do not include medical information about yourself or another person from which you or the person could be identified.
- Spell out any abbreviations you use
- For copyright reasons, comment forms do not include attachments such as research articles, letters or leaflets (for copyright reasons). We return comments forms that have attachments without reading them. The stakeholder may resubmit the form without attachments, but it must be received by the deadline.

You can see any guidance that we have produced on topics related to this guideline by checking [NICE Pathways](#).

Note: We reserve the right to summarise and edit comments received during consultations, or not to publish them at all, if we consider the comments are too long, or publication would be unlawful or otherwise inappropriate.

Comments received during our consultations are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the comments we received, and are not endorsed by NICE, its officers or advisory Committees.

Please return to: **[insert email address]**